Status:
COMPLETED
18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
Life Molecular Imaging SA
British Heart Foundation
Conditions:
Thrombosis Cardiac
Aortic Valve Disease
Eligibility:
All Genders
50+ years
Brief Summary
18F-GP1 binds with high affinity to the glycoprotein IIb/IIIa receptors on activated platelets. 18F-GP1 PET-CT has recently demonstrated favourable safety, pharmacokinetic, biodistribution and diagnos...
Detailed Description
Aortic stenosis is the most common reason for valvular interventions in the developed world, with rates projected to increase as the population ages. Aortic valve replacement remains the only recognis...
Eligibility Criteria
Inclusion
- ability to give informed consent
- \>1 month post-surgical or transcatheter aortic valve replacement
Exclusion
- Inability to give informed consent
- Pregnancy or breastfeeding
- Contraindications to iodinated contrast
- Contraindications to anticoagulation
- Use of anticoagulants during the post-operative period prior to screening
- Extreme claustrophobia
- Chronic kidney disease (with estimated glomerular filtration rate \<30 mL/min/1.73m2)
- Metastatic malignancy
- Inability to tolerate the supine position
Key Trial Info
Start Date :
October 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2021
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04073875
Start Date
October 22 2019
End Date
October 13 2021
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Edinburgh
Edinburgh, United Kingdom